Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIONASDAQ:FRTXNASDAQ:KTTAOTCMKTS:NSPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$3.61+9.4%$6.58$3.15▼$53.10$6.28M3.1295,495 shs104,539 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsKTTAPasithea Therapeutics$0.76+3.4%$1.04$0.70▼$7.50$5.65M0.342.08 million shs123,334 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics0.00%-2.70%-11.74%-63.54%-78.12%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%-1.58%KTTAPasithea Therapeutics0.00%+1.47%-21.76%-41.62%-85.00%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDIOCardio Diagnostics3.2443 of 5 stars3.55.00.00.02.21.70.6FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics1.887 of 5 stars0.05.00.00.03.31.70.6NSPXInspyr TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 3.00Buy$60.001,562.05% UpsideFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/ANSPXInspyr Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$40K157.04N/AN/A$7.10 per share0.51FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56KTTAPasithea TherapeuticsN/AN/AN/AN/A$10.60 per shareN/ANSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-28,539.39%-84.55%-74.63%8/12/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AKTTAPasithea Therapeutics-$13.90M-$10.60N/A∞N/AN/A-88.14%-81.21%8/12/2025 (Estimated)NSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/ALatest NSPX, CDIO, FRTX, and KTTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A19.4719.47FRTXFresh Tracks TherapeuticsN/AN/AN/AKTTAPasithea TherapeuticsN/A3.843.84NSPXInspyr TherapeuticsN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%FRTXFresh Tracks Therapeutics25.04%KTTAPasithea Therapeutics23.92%NSPXInspyr Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics22.30%FRTXFresh Tracks Therapeutics0.23%KTTAPasithea Therapeutics16.30%NSPXInspyr Therapeutics0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableKTTAPasithea Therapeutics37.44 million6.23 millionNot OptionableNSPXInspyr Therapeutics1543.15 millionN/ANot OptionableNSPX, CDIO, FRTX, and KTTA HeadlinesRecent News About These CompaniesInspyr Supports Breast Cancer Survivors with 'More Than Just a Pink Ribbon' EventOctober 1, 2024 | msn.comEWTX Edgewise Therapeutics, Inc.April 4, 2024 | seekingalpha.comFAST joins with University of Pennsylvania to develop investigational AAV gene therapy for Angelman syndromeOctober 18, 2023 | news-medical.netNMemo Therapeutics gets US FDA fast track designation for AntiBKV as treatment of BKV infection in renal transplant patientsMay 5, 2023 | pharmabiz.comPDecibel Therapeutics gets European orphan drug designation for lead gene therapy candidate DB-OTOApril 3, 2023 | pharmabiz.comPBrainStorm Cell Therapeutics announces US FDA committee to review BLA for NurOwn to treat amyotrophic lateral sclerosisMarch 29, 2023 | pharmabiz.comPKuria Therapeutics completes US FDA pre-IND consultation for topical Nrf2 activator for corneal endothelial diseaseMarch 22, 2023 | pharmabiz.comPCombined Therapeutics’ mRNA vaccine platform receives US patentMarch 16, 2023 | pharmabiz.comPTG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, PredictionsMarch 4, 2023 | benzinga.comInspyr Therapeutics Announces New Holding Company Structure and Reverse Stock SplitOctober 12, 2021 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPX, CDIO, FRTX, and KTTA Company DescriptionsCardio Diagnostics NASDAQ:CDIO$3.61 +0.31 (+9.39%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.50 -0.11 (-2.91%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Pasithea Therapeutics NASDAQ:KTTA$0.76 +0.03 (+3.41%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.70 -0.06 (-7.91%) As of 04:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Inspyr Therapeutics OTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
